Learn
Patient Navigation Program
Find Treatment Options
Brain Tumor Symptoms
Guide For Newly Diagnosed
Checklist For Newly Diagnosed
Video Library
Noteworthy Treatments
Brain Tumor News
Survivor Stories
Fundraising
DC-Vax
Onc-201 for DIPG/DMG
Optune
Temodar (Temozolomide)
GammaTile
Newsletter
Subscribe
Change Email
Unsubscribe
Archives
Virtual Trial
What is it?
Join
Submit An Update
Map of Participants
Resources
Discussion Forum
Copayment Assistance Program
Drug Discount Card
Brain Tumor Centers
Support Groups
Links To Other Resources
Books
Memorials
About Us
Musella Foundation
Research Grants
Recent Additions To Website
Privacy Policy
Our Sponsors
Financials
Contact
donations
News and Press Releases about the Novocure Optune™ System
01/06/16
Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System
Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
Optune can now be used even if you have a non programmable shunt!
FDA Approves Optune for Newly Diagnosed Glioblastoma Patients.
Risk of death reduced by 37%!
Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF Therapy at the 4thQuadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)
Centers for Medicare and Medicaid Services (CMS) Has Established Permanent Billing Codes for the NovoTTF-100A System
NOVOCURE PRESENTS RESULTS FROM BREAST CANCER PILOT STUDY (Mentions GBM also)
FDA Approves the NovoTTF-100A System for the Treatment of Patients with Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
Novel Electric Helmet Slows Brain Tumors Without Chemotherapy Side Effects
NOVOCURE REPORTS DATA SHOWING TTF THERAPY IN COMBINATION WITH CHEMOTHERAPY HAS THE POTENTIAL TO INCREASE OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (Editor`s Note: Although not related to brain tumors, this shows that the Novo TTF device has a strong effect on cancer.
Novocure Establishes Initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields (TTFields) Therapy
SUCCESSFUL PHASE III CLINICAL TRIAL RESULTS REPORTED FOR NOVOCURE'S NOVEL MEDICAL DEVICE FOR TREATMENT OF RECURRENT GLIOBLASTOMA
STUDIES SHOW NOVEL DEVICE MAY ENHANCE CHEMOTHERAPY TREATMENT IN BRAIN TUMORS
NovoCure, Ltd., Announces the Closing of a Financing Round Including New Investors Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures
Updated Survival Data from Study Comparing TTF (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
Fighting brain cancer with electricity
Professor Zvi Ram Presents Phase III Recurrent Glioblastoma Survival and Quality of Life Data from the First Pivotal Study of the NovoTTF-100A at the 15th Annual Society for Neuro-Oncology (SNO) Scientific Meeting
NOVEL DEVICE SHOWN TO BENEFIT SURVIVAL FOR BRAIN CANCER PATIENTS WHEN COMBINED WITH CHEMOTHERAPY
Innovative device to treat brain cancer shows promise in early studies
FDA votes to approve Novocure Device
Activism Alert: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!
Experimental Device Used To Treat Deadly Brain Cancer
Activism Alert Update: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!
Electric Fields Kill Tumors A promising device uses electric fields to destroy cancer cells in the brain.
FDA clears first-of-a-kind device for brain cancer (Mentions Musella Foundation!)
Device for Glioblastoma May Offer Advantage Over Chemo
IBTA E News October 2010
Electrifying new brain cancer weapon
Patient Receives First Prescription for FDA-Approved Brain Tumor Treatment
Letter writing campaign now closed!
Electrical Device for Cancer Treatment Polarizes Audiences
New Brain Tumor Videos Added to virtualtrials.org
IBTA E News April 2011
Brain Cancer Zapper
International Brain Tumor Alliance Newsletter!
IBTA E News November-December 2011
Device with AC current is comparable to chemo for recurrent glioblastoma
ET-03. THE EFFICACY OF TEMOZOLOMIDE IN VITRO AND IN PATIENTS WITH NEWLY DIAGNOSED GBM IS ENHANCED BY ADJUVANT EXPOSURE TO ALTERNATING ELECTRIC FIELDS (TTFIELDS)
FDA panel: Benefits outweigh risks of non-invasive therapy for glioblastoma
IBTA E NEWS AUGUST-SEPTEMBER 2011
FDA Advisory Panel Endorses New GBM Treatment
IBTA E News March 2011
IBTA E News February 2011
IBTA E-News May 2010
IBTA E-News March 2010
Heroes of Hope Race and Kids Fun Run to Benefit Brain Tumor Research
BRAIN TUMOUR SUPPORTERS WALK THE EQUIVALENT OF MORE THAN TWICE AROUND THE WORLD
200,000 PEOPLE WORLDWIDE AFFECTED EACH YEAR BY HIGHLY MALIGNANT BRAIN TUMOURS
University Evaluates New Device To Treat Brain Tumors
Click on the links below for more information on Optune™.
Educational videos
Open Houses
[Link to Optune.com list of open houses: Opens in new window]
Find a Doctor who uses Optune™
Frequently Asked Questions
Scientific articles about Optune™
News articles and press releases about the Optune™ system
Financial Resources
Online support group for people interested in Optune™
The Optune™ trial details on Clinical Trials.gov
The Optune™ Patient Website
The "Official" Novocure company Website
Disclosure: the Novocure company is a sponsor of our organization.
Our privacy / cookie policy has changed.
Click HERE to read it!
Please ensure Javascript is enabled for purposes of
website accessibility